Viloxazine: A New Non-Stimulant Treatment for Attention-Deficit/Hyperactivity Disorder (ADHD)
DOI:
https://doi.org/10.12775/JEHS.2024.58.006Keywords
viloxazine, ADHD treatment, ADHD, attention deficit hyperactivity disorder, adhd non-stimulant drug, adhd non-stimulant treatment, adhd non-stimulants, attention deficit hyperactivity disorder treatment, SPN-812Abstract
Introduction
Viloxazine is an antidepressant medication classified as an SNRI (serotonin and norepinephrine reuptake inhibitor). In April 2021, it received FDA approval in the United States for the treatment of ADHD in children aged 6 to 17. Subsequently, in May 2022, it was also approved for the treatment of adults with ADHD [1]. Viloxazine, available in extended-release capsules, represents novel non-stimulant medication option for patients with ADHD.
Aim of the study
Our aim was to review the viloxazine in the fields of ADHD treatment, summarize current knowledge and analyze the first treatment results.
Methods and materials
A review of the literature available in the PubMed database was performed, using the key words: „Viloxazine" ; „ADHD treatment" ; „ADHD”, „attention deficit hyperactivity disorder”, „attention deficit hyperactivity disorder treatment”; „ADHD non-stimulant treatment”; „ADHD non-stimulant”; „ADHD non-stimulant drugs”, „SPN-812”
Conclusion
Viloxazine presents a promising non-stimulant alternative for ADHD treatment with more favorable pharmacokinetics, new way of possible administration and fewer adverse effects, particularly within the cardiovascular system, than other available ADHD medication options. While these findings are encouraging, continual research is imperative to establish the long-term safety profile.
References
O’Connor L, Carbone S, Gobbo A, Gamble H, Faraone SV. Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management. Expert Rev Clin Pharmacol [Internet]. August 22, 2023 [cited January 8, 2024]:1-14. Available at: https://doi.org/10.1080/17512433.2023.2249414
Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Busse GD, Chowdhry F, Cutler AJ, Jones NJ, Findling RL, Schwabe S. A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder. J Clin Psychopharmacol [Internet]. May 8, 2021 [cited January 7, 2024];41(4):370-80. Available at: https://doi.org/10.1097/jcp.0000000000001404
Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, Busse GD, Cutler AJ, Jones NJ, Findling RL, Schwabe S. A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children. Clin Ther [Internet]. August 2020 [cited January 7, 2024];42(8):1452-66. Available at: https://doi.org/10.1016/j.clinthera.2020.05.021
Robinson CL, Parker K, Kataria S, Downs E, Supra R, Kaye AD, Viswanath O, Urits I. Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder. Health Psychol Res [Internet]. September 23, 2022 [cited January 8, 2024];10(3). Available at: https://doi.org/10.52965/001c.38360
Newcorn JH, Krone B, Dittmann RW. Nonstimulant Treatments for ADHD. Child Adolesc Psychiatr Clin North Am [Internet]. May 2022 [cited January 8, 2024]. Available at: https://doi.org/10.1016/j.chc.2022.03.005
Faison SL, Fry N, Adewole T, Odebo O, Schwabe S, Wang Z, Maletic V, Nasser A. Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults. Clin Drug Investig [Internet]. December 23, 2020 [cited January 7, 2024]. Available at: https://doi.org/10.1007/s40261-020-00992-6
Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, Busse GD, Melyan Z, Cutler AJ, Findling RL, Schwabe S. A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD. Psychopharmacol Bull. 2021 Mar 16;51(2):43-64. PMID: 34092822; PMCID: PMC8146561
Mathew BM, Pellegrini MV. Viloxazine. August 17, 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 35015448.
Nazarova VA, Sokolov AV, Chubarev VN, Tarasov VV, Schiöth HB. Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. Front Pharmacol [Internet]. November 17, 2022 [cited January 8, 2024];13. Available at: https://doi.org/10.3389/fphar.2022.1066988
Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol [Internet]. August 2020 [cited January 8, 2024];Volume 12:285-300. Available at: https://doi.org/10.2147/jep.s256586
Singh A, Balasundaram MK, Singh A. Viloxazine for Attention-Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis of Randomized Clinical Trials. J Central Nerv Syst Dis [Internet]. January 2022 [cited January 8, 2024];14:117957352210925. Available at: https://doi.org/10.1177/11795735221092522
Nasser A, Hull JT, Chaturvedi SA, Liranso T, Odebo O, Kosheleff AR, Fry N, Cutler AJ, Rubin J, Schwabe S, Childress A. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder. CNS Drugs [Internet]. July 27, 2022 [cited January 7, 2024]. Available at: https://doi.org/10.1007/s40263-022-00938-w
Radonjić NV, Bellato A, Khoury NM, Cortese S, Faraone SV. Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis. CNS Drugs [Internet]. May 11, 2023 [cited January 8, 2024]. Available at: https://doi.org/10.1007/s40263-023-01005-8
Pozzi M, Bertella S, Gatti E, Peeters GG, Carnovale C, Zambrano S, Nobile M. Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD). Expert Opin Emerg Drugs [Internet]. September 25, 2020 [cited January 8, 2024];25(4):395-407. Available at: https://doi.org/10.1080/14728214.2020.1820481
Ryst E, Childress A. An updated safety review of the current drugs for managing ADHD in children. Expert Opin Drug Saf [Internet]. October 16, 2023 [cited January 8, 2024]. Available at: https://doi.org/10.1080/14740338.2023.2271392
Findling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, O’Neal W, Newcorn JH. Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status. CNS Drugs [Internet]. May 18, 2021 [cited January 8, 2024];35(6):643-53. Available at: https://doi.org/10.1007/s40263-021-00825-w
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Viloxazine. August 20, 2021. PMID: 34542988.
Faraone SV, Gomeni R, Hull JT, Busse GD, Melyan Z, Rubin J, Nasser A. Executive Function Outcome of Treatment with Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Post-Hoc Analysis of Four Randomized Clinical Trials. Pediatr Drugs [Internet]. September 15, 2021 [cited January 8, 2024]. Available at: https://doi.org/10.1007/s40272-021-00470-2
Faraone SV, Gomeni R, Hull JT, Busse GD, Lujan B, Rubin J, Nasser A. Response of peer relations and social activities to treatment with viloxazine extended‐release capsules (Qelbree ® ): A post hoc analysis of four randomized clinical trials of children and adolescents with attention‐deficit/hyperactivity disorder. Brain Behav [Internet]. February 27, 2023 [cited January 8, 2024]. Available at: https://doi.org/10.1002/brb3.2910
Faraone SV, Gomeni R, Hull JT, Busse GD, Melyan Z, Rubin J, Nasser A. A post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit/hyperactivity disorder. Eur Child Amp Adolesc Psychiatry [Internet]. September 28, 2021 [cited January 7, 2024]. Available at: https://doi.org/10.1007/s00787-021-01877-5
Nasser A, Faraone SL, Liranso T, Adewole T, Busse GD, Fava M, Kleiman RB, Schwabe S. Evaluation of the Effect of SPN-812 (Viloxazine Extended-Release) on QTc Interval in Healthy Adults. J Clin Psychiatry [Internet]. October 13, 2020 [cited January 7, 2024];81(6). Available at: https://doi.org/10.4088/jcp.20m13395
Nasser A, Liranso T, Adewole T, Fry N, Hull JT, Chowdhry F, Busse GD, Melyan Z, Cutler AJ, Findling RL, Schwabe S. Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial. Clin Ther [Internet]. April 2021 [cited January 7, 2024];43(4):684-700. Available at: https://doi.org/10.1016/j.clinthera.2021.01.027
Price MZ, Price RL. Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder. CNS Drugs [Internet]. July 10, 2023 [cited January 8, 2024]. Available at: https://doi.org/10.1007/s40263-023-01023-6
Williams OC, Prasad S, McCrary A, Jordan E, Sachdeva V, Deva S, Kumar H, Mehta J, Neupane P, Gupta A. Adult ADHD: a comprehensive review. Ann Med Amp Surg [Internet]. April 13, 2023 [cited January 8, 2024];Publish Ahead of Print. Available at: https://doi.org/10.1097/ms9.0000000000000631
Faraone SV, Gomeni R, Hull JT, Chaturvedi SA, Busse GD, Melyan Z, O'Neal W, Rubin J, Nasser A. Predicting Efficacy of Viloxazine Extended-Release Treatment in Adults with ADHD Using an Early Change in ADHD Symptoms: Machine Learning Post Hoc Analysis of a Phase 3 Clinical Trial. Psychiatry Res [Internet]. October 2022 [cited January 7, 2024]:114922. Available at: https://doi.org/10.1016/j.psychres.2022.114922
Raible H, D’Souza MS. Extended-Release Viloxazine for the Treatment of Attention-Deficit Hyperactivity Disorder in School-Age Children and Adolescents. Ann Pharmacother [Internet]. April 5, 2023]:106002802311632. Available at: https://doi.org/10.1177/10600280231163252
Wang Z, Kosheleff AR, Adeojo LW, Odebo O, Liranso T, Schwabe S, Nasser A. Impact of a High-Fat Meal and Sprinkled Administration on the Bioavailability and Pharmacokinetics of Viloxazine Extended-Release Capsules (QelbreeTM) in Healthy Adult Subjects. Eur J Drug Metab Pharmacokinet [Internet]. October 15, 2021 [cited January 7, 2024];47(1):69-79. Available at: https://doi.org/10.1007/s13318-021-00729-6
Childress A, Sottile R, Khanbijian S. Viloxazine extended-release capsules for the treatment of attention-deficit/ hyperactivity disorder in adult patients. Expert Rev Neurother [Internet]. October 17, 2023 [cited January 8, 2024]:1-9. Available at: https://doi.org/10.1080/14737175.2023.2265068
Lamb YN. Viloxazine: Pediatric First Approval. Pediatr Drugs [Internet]. May 26, 2021 [cited January 8, 2024];23(4):403-9. Available at: https://doi.org/10.1007/s40272-021-00453-3
Tan X, Xu Y, Wang S, Li J, Hu C, Chen Z, Cheng Q, Wang Z. Efficacy and Safety of SPN-812 (Extended-Release Viloxazine) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. Brain Sci [Internet]. November 24, 2023 [cited January 8, 2024];13(12):1627. Available at: https://doi.org/10.3390/brainsci13121627
Childress A, Burton S. Evaluating the pharmacokinetics of extended release viloxazine in the treatment of children with attention-deficit/hyperactivity disorder. Expert Opin Drug Metab Amp Toxicol [Internet]. July 18, 2022 [cited January 8, 2024]. Available at: https://doi.org/10.1080/17425255.2022.2103406
Faison SL, Fry N, Adewole T, Odebo O, Wang Z, Maletic V, Nasser A. Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults. J Clin Psychopharmacol [Internet]. February 12, 2021 [cited January 7, 2024];41(2):155-62. Available at: https://doi.org/10.1097/jcp.0000000000001361
Nasser A, Gomeni R, Wang Z, Kosheleff AR, Xie L, Adeojo LW, Schwabe S. Population Pharmacokinetics of Viloxazine Extended‐Release Capsules in Pediatric Subjects With Attention Deficit/Hyperactivity Disorder. J Clin Pharmacol [Internet]. August 8, 2021 [cited January 7, 2024]. Available at: https://doi.org/10.1002/jcph.1940
Jumaili WA, Mian N, Jain S. Viloxazine-Associated Partial Priapism in Children. Prim Care Companion CNS Disord [Internet]. August 22, 2023 [cited January 8, 2024];25(4). Available at: https://doi.org/10.4088/pcc.22cr03458
Lorman WJ. Viloxazine (Qelbree™). J Addict Nurs [Internet]. April 2022 [cited January 8, 2024];33(2):114-5. Available at: https://doi.org/10.1097/jan.0000000000000459
Mather K, Condren M. Extended-Release Viloxazine for Children and Adolescents With Attention Deficit Hyperactivity Disorder. J Pediatr Pharmacol Ther [Internet]. May 1, 2022 [cited January 8, 2024];27(5):409-14. Available at: https://doi.org/10.5863/1551-6776-27.5.409
Ban TA, McEvoy JP, Wilson WH. Viloxazine: a Review of the Literature. Int Pharmacopsychiatry [Internet]. 1980 [cited January 8, 2024];15(2):118-23. Available at: https://doi.org/10.1159/000468422
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Wiktoria Wilanowska, Anna Greguła, Karol Stachyrak, Dawid Mika, Aleksandra Kłos, Kamila Turek, Maciej Lambach, Mateusz Pawlicki, Aleksandra Mazurek, Bartosz Mazur
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 815
Number of citations: 0
